3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Neoplasm Metastasis
2
Triple Negative Breast Neoplasms
1
Polycystic Ovary Syndrome
1
Pleural Effusion, Malignant
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mycosis Fungoides
1
Menstruation Disturbances
1
Lymphoma
1
Hyperandrogenism
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Gemcitabine
74
Fluorouracil
31
Oxaliplatin
21
Leucovorin
21
130-nm albumin-bound paclitaxel
17
Capecitabine
14
Irinotecan
12
Albumin-Bound Paclitaxel
10
irinotecan sucrosofate
8
Radiotherapy
6
Taxes
5
Erlotinib Hydrochloride
5
folfirinox
4
rubitecan
3
Surgical Procedures, Operative
3
Specimen Handling
3
Pancreaticojejunostomy
3
Neoadjuvant Therapy
3
Drug Therapy
3
Cisplatin
3
Chemotherapy, Adjuvant
3
ruxolitinib
2
masitinib
2
dehydroftorafur
2
Saline Solution
2
S 1 (combination)
2
Paclitaxel
2
GV1001 peptide
2
Fentanyl
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Pancreatic Neoplasms
×
Doxycycline
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn